A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: 1.5% QLM3003; Drug: 2% QLM3003; Drug: Vehicle (Placebo) Sponsor: Qilu Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Foam Tape Allergy a Sticky Situation
Conditions: Medical Adhesive Allergy; Dermatologic Conditions; Dermatologic Lesions Intervention: Other: 2x2 inch piece of 3M microfoam adhesive Sponsor: CHRISTUS Health Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: 1.5% QLM3003; Drug: 2% QLM3003; Drug: Vehicle (Placebo) Sponsors: Qilu Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: SAR444656 (KT-474); Drug: Placebo Sponsors: Sanofi; Kymera Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Foam Tape Allergy a Sticky Situation
Conditions: Medical Adhesive Allergy; Dermatologic Conditions; Dermatologic Lesions Interventions: Other: 2x2 inch piece of 3M microfoam adhesive Sponsors: CHRISTUS Health Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Addressing Inequity in Dermatology
Condition: Dermatologic Disease Intervention: Sponsors: University of Manchester; Dowager Countess Eleanor Peel Trust Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus); Sjogren's Syndrome; Systemic Scleroderma; Dermatomyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Intervention: Biological: CD19 targeted CAR-T cells Sponsor: Chongqing Precision Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Addressing Inequity in Dermatology
Conditions: Dermatologic Disease Sponsors: University of Manchester; Dowager Countess Eleanor Peel Trust Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus); Sjogren ' s Syndrome; Systemic Scleroderma; Dermatomyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Interventions: Biological: CD19 targeted CAR-T cells Sponsors: Chongqing Precision Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Evaluation of Microinjected Amnion-derived Collagen by Dermapen in the Smoothing of Skin Wrinkles
Condition: Using of Amnion Collagen Matrix in Facial Rejuvenation Interventions: Biological: Amnion collagen; Biological: Platelet-rich plasma Sponsors: Egyptian Atomic Energy Authority; Waleed Nemr,Egyptian Atomic Energy Authority Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: BxC-I17e; Drug: Placebo Sponsor: Brexogen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: BxC-I17e; Drug: Placebo Sponsor: Brexogen Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Evaluation of Microinjected Amnion-derived Collagen by Dermapen in the Smoothing of Skin Wrinkles
Condition: Using of Amnion Collagen Matrix in Facial Rejuvenation Interventions: Biological: Amnion collagen; Biological: Platelet-rich plasma Sponsors: Egyptian Atomic Energy Authority; Waleed Nemr,Egyptian Atomic Energy Authority Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: BxC-I17e; Drug: Placebo Sponsor: Brexogen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: BxC-I17e; Drug: Placebo Sponsor: Brexogen Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials